Last reviewed · How we verify
Mycophenolic Acid (Myfortic)
Mycophenolic Acid (Myfortic) is a Immunosuppressant; IMPDH inhibitor Small molecule drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved for Prevention of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, Maintenance immunosuppression in combination with other agents (calcineurin inhibitors, corticosteroids). Also known as: Cellcept; Myfortic, mycophenolic acid enteric coated.
Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing proliferation of T and B lymphocytes to prevent organ rejection.
Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing proliferation of T and B lymphocytes to prevent organ rejection. Used for Prevention of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, Maintenance immunosuppression in combination with other agents (calcineurin inhibitors, corticosteroids).
At a glance
| Generic name | Mycophenolic Acid (Myfortic) |
|---|---|
| Also known as | Cellcept; Myfortic, mycophenolic acid enteric coated |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Immunosuppressant; IMPDH inhibitor |
| Target | Inosine monophosphate dehydrogenase (IMPDH) type II |
| Modality | Small molecule |
| Therapeutic area | Immunology; Transplantation |
| Phase | FDA-approved |
Mechanism of action
Mycophenolic acid is a non-competitive, selective inhibitor of IMPDH type II, the enzyme responsible for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, it preferentially inhibits T and B cell proliferation while sparing other cell types, thereby reducing immune-mediated rejection of transplanted organs. Myfortic is an enteric-coated formulation designed for improved gastrointestinal tolerability.
Approved indications
- Prevention of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants
- Maintenance immunosuppression in combination with other agents (calcineurin inhibitors, corticosteroids)
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Leukopenia
- Anemia
- Infection
- Headache
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Tocilizumab in Lung Transplantation (PHASE2)
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
- Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis (NA)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolic Acid (Myfortic) CI brief — competitive landscape report
- Mycophenolic Acid (Myfortic) updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI
Frequently asked questions about Mycophenolic Acid (Myfortic)
What is Mycophenolic Acid (Myfortic)?
How does Mycophenolic Acid (Myfortic) work?
What is Mycophenolic Acid (Myfortic) used for?
Who makes Mycophenolic Acid (Myfortic)?
Is Mycophenolic Acid (Myfortic) also known as anything else?
What drug class is Mycophenolic Acid (Myfortic) in?
What development phase is Mycophenolic Acid (Myfortic) in?
What are the side effects of Mycophenolic Acid (Myfortic)?
What does Mycophenolic Acid (Myfortic) target?
Related
- Drug class: All Immunosuppressant; IMPDH inhibitor drugs
- Target: All drugs targeting Inosine monophosphate dehydrogenase (IMPDH) type II
- Manufacturer: University of North Carolina, Chapel Hill — full pipeline
- Therapeutic area: All drugs in Immunology; Transplantation
- Indication: Drugs for Prevention of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants
- Indication: Drugs for Maintenance immunosuppression in combination with other agents (calcineurin inhibitors, corticosteroids)
- Also known as: Cellcept; Myfortic, mycophenolic acid enteric coated
- Compare: Mycophenolic Acid (Myfortic) vs similar drugs
- Pricing: Mycophenolic Acid (Myfortic) cost, discount & access